Financials Neuronetics, Inc.

Equities

STIM

US64131A1051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
3.8 USD -0.78% Intraday chart for Neuronetics, Inc. -12.04% +31.03%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 83.66 210.8 117.6 187 83.91 113.9 - -
Enterprise Value (EV) 1 83.66 210.8 117.6 187 83.91 113.9 113.9 113.9
P/E ratio -2.84 x -7.61 x -3.66 x -4.98 x -2.76 x -4.11 x -5.96 x -9.16 x
Yield - - - - - - - -
Capitalization / Revenue 1.34 x 4.28 x 2.13 x 2.87 x 1.18 x 1.44 x 1.27 x 1.11 x
EV / Revenue 1.34 x 4.28 x 2.13 x 2.87 x 1.18 x 1.44 x 1.27 x 1.11 x
EV / EBITDA -3.44 x -9.59 x -4.5 x -7.57 x -2.94 x -10.2 x -81.4 x 24.2 x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 18,632 18,975 26,368 27,221 28,933 29,975 - -
Reference price 2 4.490 11.11 4.460 6.870 2.900 3.800 3.800 3.800
Announcement Date 3/3/20 3/2/21 3/8/22 3/7/23 3/5/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 62.66 49.24 55.31 65.21 71.35 79.12 89.41 103
EBITDA 1 -24.29 -21.99 -26.11 -24.72 -28.55 -11.2 -1.4 4.7
EBIT 1 -26.93 -22.31 -27.56 -35.11 -30.55 -21.59 -13.88 -8.044
Operating Margin -42.98% -45.3% -49.83% -53.85% -42.82% -27.29% -15.52% -7.81%
Earnings before Tax (EBT) 1 -29.04 -27.45 -31.19 -37.16 -30.19 -29.73 -21.4 -14.53
Net income 1 -29.04 -27.45 -31.19 -37.16 -30.19 -29.73 -21.4 -14.53
Net margin -46.35% -55.75% -56.39% -56.99% -42.31% -37.57% -23.94% -14.1%
EPS 2 -1.580 -1.460 -1.220 -1.380 -1.050 -0.9250 -0.6375 -0.4150
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/3/20 3/2/21 3/8/22 3/7/23 3/5/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 13.8 15.02 14.18 16.33 16.5 18.2 15.54 17.61 17.84 20.31 17.12 19.47 20.01 22.49 19.52
EBITDA 1 -6.942 -6.279 -7.564 -7.255 -4.889 -5.009 -7.586 -4.828 -6.517 -3.924 -4.8 -3.3 -2.7 -0.4 -
EBIT 1 -7.182 -6.908 -10.14 -9.796 -7.454 -7.726 -9.907 -7.349 -8.871 -4.427 -8.178 -5.703 -5.526 -2.835 -7.713
Operating Margin -52.05% -45.99% -71.47% -59.99% -45.18% -42.46% -63.75% -41.73% -49.71% -21.79% -47.76% -29.29% -27.61% -12.61% -39.51%
Earnings before Tax (EBT) 1 -8.151 -7.635 -10.84 -10.42 -7.609 -8.289 -10.52 -4.901 -9.391 -5.377 -10.05 -7.574 -7.397 -4.706 -9.556
Net income 1 -8.151 -7.635 -10.84 -10.42 -7.609 -8.289 -10.52 -4.901 -9.391 -5.377 -10.05 -7.574 -7.397 -4.706 -9.556
Net margin -59.07% -50.83% -76.43% -63.83% -46.12% -45.55% -67.7% -27.83% -52.63% -26.47% -58.69% -38.91% -36.96% -20.93% -48.95%
EPS 2 -0.3100 -0.2900 -0.4100 -0.3900 -0.2800 -0.3000 -0.3800 -0.1700 -0.3300 -0.1900 -0.3100 -0.2375 -0.2325 -0.1500 -0.2233
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/9/21 3/8/22 5/12/22 8/2/22 11/8/22 3/7/23 5/9/23 8/8/23 11/7/23 3/5/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex - - - - - - - -
Capex / Sales - - - - - - - -
Announcement Date 3/3/20 3/2/21 3/8/22 3/7/23 3/5/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.8 USD
Average target price
7 USD
Spread / Average Target
+84.21%
Consensus
  1. Stock Market
  2. Equities
  3. STIM Stock
  4. Financials Neuronetics, Inc.